{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:31:46Z","timestamp":1789471906769,"version":"build-2803163510"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Lipid Research"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.plipres.2017.05.001","type":"journal-article","created":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T09:18:19Z","timestamp":1494580699000},"page":"16-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["HDL abnormalities in familial hypercholesterolemia: Focus on biological functions"],"prefix":"10.1016","volume":"67","author":[{"given":"Shiva","family":"Ganjali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Abbas","family":"Momtazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":false,"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petri T.","family":"Kovanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan A.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.plipres.2017.05.001_bb0005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1152\/ajplegacy.1954.179.2.333","article-title":"Ultracentrifugal studies of high density serum lipoproteins in clinically healthy adults","volume":"179","author":"Delalla","year":"1954","journal-title":"Am. J. Phys."},{"issue":"6","key":"10.1016\/j.plipres.2017.05.001_bb0010","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/00041433-199112000-00005","article-title":"Lipoprotein particle measurement: an alternative approach to classification of lipid disorders","volume":"2","author":"Fruchart","year":"1991","journal-title":"Curr. Opin. Lipidol."},{"issue":"10","key":"10.1016\/j.plipres.2017.05.001_bb0015","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.molmed.2011.05.013","article-title":"Biological activities of HDL subpopulations and their relevance to cardiovascular disease","volume":"17","author":"Camont","year":"2011","journal-title":"Trends Mol. Med."},{"issue":"1","key":"10.1016\/j.plipres.2017.05.001_bb0020","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jacl.2015.10.006","article-title":"Small, dense high-density lipoprotein 3 particles exhibit defective antioxidative and anti-inflammatory function in familial hypercholesterolemia: partial correction by low-density lipoprotein apheresis","volume":"10","author":"Hussein","year":"2016","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1016\/j.plipres.2017.05.001_bb0025","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1194\/jlr.R800097-JLR200","article-title":"The HDL proteome: a marker\u2013and perhaps mediator\u2013of coronary artery disease","volume":"50","author":"Heinecke","year":"2009","journal-title":"J. Lipid Res."},{"issue":"12","key":"10.1016\/j.plipres.2017.05.001_bb0030","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1172\/JCI30163","article-title":"Molecular regulation of HDL metabolism and function: implications for novel therapies","volume":"116","author":"Rader","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.plipres.2017.05.001_bb0035","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/emmm.201200224","article-title":"Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease","volume":"4","author":"Besler","year":"2012","journal-title":"EMBO Mol. Med."},{"issue":"7","key":"10.1016\/j.plipres.2017.05.001_bb0040","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.bbalip.2016.03.004","article-title":"HDL functionality in reverse cholesterol transport--challenges in translating data emerging from mouse models to human disease","volume":"1861","author":"Lee-Rueckert","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"8","key":"10.1016\/j.plipres.2017.05.001_bb0045","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/eurheartj\/ehp538","article-title":"The risk of tendon xanthomas in familial hypercholesterolaemia is influenced by variation in genes of the reverse cholesterol transport pathway and the low-density lipoprotein oxidation pathway","volume":"31","author":"Oosterveer","year":"2010","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.plipres.2017.05.001_bb0050","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1021\/cr020466v","article-title":"HDL: the metabolism, function, and therapeutic importance","volume":"104","author":"Wang","year":"2004","journal-title":"Chem. Rev."},{"key":"10.1016\/j.plipres.2017.05.001_bb0055","first-page":"205","article-title":"Current guidelines for high-density lipoprotein cholesterol in therapy and future directions","volume":"10","author":"Subedi","year":"2014","journal-title":"Vasc. Health Risk Manag."},{"issue":"25 Suppl 2","key":"10.1016\/j.plipres.2017.05.001_bb0060","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.plipres.2017.05.001_bb0065","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"I. Treating to new targets, HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.plipres.2017.05.001_bb0070","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.2937","article-title":"The not-so-simple HDL story: is it time to revise the HDL cholesterol hypothesis?","volume":"18","author":"Rader","year":"2012","journal-title":"Nat. Med."},{"issue":"25","key":"10.1016\/j.plipres.2017.05.001_bb0075","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.2174\/0929867321666140414103455","article-title":"Subfractions and subpopulations of HDL: an update","volume":"21","author":"Rizzo","year":"2014","journal-title":"Curr. Med. Chem."},{"issue":"9841","key":"10.1016\/j.plipres.2017.05.001_bb0080","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.plipres.2017.05.001_bb0085","doi-asserted-by":"crossref","first-page":"b92","DOI":"10.1136\/bmj.b92","article-title":"Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis","volume":"338","author":"Briel","year":"2009","journal-title":"BMJ"},{"issue":"19","key":"10.1016\/j.plipres.2017.05.001_bb0090","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.jacc.2016.08.038","article-title":"High-density lipoprotein cholesterol and cause-specific mortality in individuals without previous cardiovascular conditions: the CANHEART study","volume":"68","author":"Ko","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"10.1016\/j.plipres.2017.05.001_bb0095","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.2215\/CJN.00730116","article-title":"High density lipoprotein cholesterol and the risk of all-cause mortality among U.S. veterans","volume":"11","author":"Bowe","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"25","key":"10.1016\/j.plipres.2017.05.001_bb0100","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.plipres.2017.05.001_bb0105","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.beem.2013.11.001","article-title":"Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality","volume":"28","author":"Barylski","year":"2014","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.plipres.2017.05.001_bb0110","doi-asserted-by":"crossref","first-page":"230","DOI":"10.5114\/aoms.2015.49816","article-title":"Dysfunctional high-density lipoprotein: not only quantity but first of all quality?","volume":"11","author":"Agouridis","year":"2015","journal-title":"Arch. Med. Sci."},{"issue":"10","key":"10.1016\/j.plipres.2017.05.001_bb0115","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1210\/jc.2012-2185","article-title":"Approach to the patient with extremely low HDL-cholesterol","volume":"97","author":"Rader","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.plipres.2017.05.001_bb0120","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.plipres.2012.03.003","article-title":"Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?","volume":"51","author":"Otocka-Kmiecik","year":"2012","journal-title":"Prog. Lipid Res."},{"issue":"4","key":"10.1016\/j.plipres.2017.05.001_bb0125","doi-asserted-by":"crossref","first-page":"844","DOI":"10.5114\/aoms.2016.60971","article-title":"Subfractions of high-density lipoprotein (HDL) and dysfunctional HDL in chronic kidney disease patients","volume":"12","author":"Rysz-G\u00f3rzy\u0144ska","year":"2016","journal-title":"Arch. Med. Sci."},{"issue":"7","key":"10.1016\/j.plipres.2017.05.001_bb0130","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S2213-8587(15)00126-6","article-title":"Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study","volume":"3","author":"Saleheen","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.plipres.2017.05.001_bb0135","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/apha.12262","article-title":"Changes in arterial function in a mouse model of human familial hypercholesterolaemia","volume":"211","author":"Brinkmann","year":"2014","journal-title":"Acta Physiol."},{"issue":"5","key":"10.1016\/j.plipres.2017.05.001_bb0140","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/MOL.0000000000000209","article-title":"Cholesterol efflux capacity, macrophage reverse cholesterol transport and cardioprotective HDL","volume":"26","author":"Hutchins","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.plipres.2017.05.001_bb0145","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12944-015-0169-0","article-title":"Lipids, blood pressure and kidney update","volume":"14","author":"Banach","year":"2015","journal-title":"Lipids Health Dis."},{"issue":"4","key":"10.1016\/j.plipres.2017.05.001_bb0150","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/jn\/136.4.877","article-title":"Triglyceride-rich HDL3 from patients with familial hypercholesterolemia are less able to inhibit cytokine release or to promote cholesterol efflux","volume":"136","author":"Ottestad","year":"2006","journal-title":"J. Nutr."},{"issue":"11","key":"10.1016\/j.plipres.2017.05.001_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111716","article-title":"A high throughput biochemical fluorometric method for measuring lipid peroxidation in HDL","volume":"9","author":"Kelesidis","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.plipres.2017.05.001_bb0160","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.bbacli.2015.01.005","article-title":"High density lipoproteins: measurement techniques and potential biomarkers of cardiovascular risk","volume":"3","author":"Hafiane","year":"2015","journal-title":"BBA Clin."},{"issue":"8","key":"10.1016\/j.plipres.2017.05.001_bb0165","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S0022-2275(20)31582-0","article-title":"A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids","volume":"42","author":"Navab","year":"2001","journal-title":"J. Lipid Res."},{"issue":"12","key":"10.1016\/j.plipres.2017.05.001_bb0170","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1194\/jlr.D018937","article-title":"A biochemical fluorometric method for assessing the oxidative properties of HDL","volume":"52","author":"Kelesidis","year":"2011","journal-title":"J. Lipid Res."},{"issue":"6","key":"10.1016\/j.plipres.2017.05.001_bb0175","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1161\/ATVBAHA.112.300552","article-title":"Diesel exhaust induces systemic lipid peroxidation and development of dysfunctional pro-oxidant and pro-inflammatory high-density lipoprotein","volume":"33","author":"Yin","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"21","key":"10.1016\/j.plipres.2017.05.001_bb0180","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1161\/CIRCULATIONAHA.104.516278","article-title":"Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice","volume":"111","author":"McMillen","year":"2005","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.plipres.2017.05.001_bb0185","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1161\/01.CIR.0000103624.14436.4B","article-title":"Inflammatory\/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment","volume":"108","author":"Ansell","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.plipres.2017.05.001_bb0190","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.112.108753","article-title":"Altered activation of endothelial anti-and pro-apoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of HDL-proteome remodeling","author":"Riwanto","year":"2013","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.plipres.2017.05.001_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095925","article-title":"eNOS activation by HDL is impaired in genetic CETP deficiency","volume":"9","author":"Gomaraschi","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.plipres.2017.05.001_bb0200","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40119-015-0037-z","article-title":"Familial hypercholesterolemia: a review of the natural history, diagnosis, and management","volume":"4","author":"Najam","year":"2015","journal-title":"Cardiol. Ther."},{"issue":"1","key":"10.1016\/j.plipres.2017.05.001_bb0205","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.atherosclerosis.2015.09.021","article-title":"Familial hypercholesterolaemia: a global call to arms","volume":"243","author":"Vallejo-Vaz","year":"2015","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.plipres.2017.05.001_bb0210","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ncpcardio0836","article-title":"Mechanisms of disease: genetic causes of familial hypercholesterolemia","volume":"4","author":"Soutar","year":"2007","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"issue":"32","key":"10.1016\/j.plipres.2017.05.001_bb0215","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur. Heart J."},{"issue":"45","key":"10.1016\/j.plipres.2017.05.001_bb0220","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"issue":"7","key":"10.1016\/j.plipres.2017.05.001_bb0225","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1161\/ATVBAHA.111.227181","article-title":"Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia","volume":"31","author":"Bellanger","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.plipres.2017.05.001_bb0230","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MOL.0b013e328353ef07","article-title":"Reverse cholesterol transport in familial hypercholesterolemia","volume":"23","author":"Guerin","year":"2012","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.plipres.2017.05.001_bb0235","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.113.002670","article-title":"Levels and changes of HDL cholesterol and apolipoprotein AI in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis","author":"Boekholdt","year":"2013","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.plipres.2017.05.001_bb0240","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jacl.2013.08.001","article-title":"High-density lipoproteins: a consensus statement from the National Lipid Association","volume":"7","author":"Toth","year":"2013","journal-title":"Journal of Clinical Lipidology"},{"issue":"10","key":"10.1016\/j.plipres.2017.05.001_bb0245","doi-asserted-by":"crossref","first-page":"10E","DOI":"10.1016\/j.amjcard.2009.09.014","article-title":"Lessons learned from the investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE) trial","volume":"104","author":"Barter","year":"2009","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.plipres.2017.05.001_bb0250","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/MOL.0b013e3283612454","article-title":"Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?","volume":"24","author":"Schaefer","year":"2013","journal-title":"Curr. Opin. Lipidol."},{"issue":"24","key":"10.1016\/j.plipres.2017.05.001_bb0255","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"6278","key":"10.1016\/j.plipres.2017.05.001_bb0260","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1126\/science.aad3517","article-title":"Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease","volume":"351","author":"Zanoni","year":"2016","journal-title":"Science"},{"issue":"1\u20132","key":"10.1016\/j.plipres.2017.05.001_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0021-9150(88)90184-0","article-title":"Removal of apolipoprotein E-enriched high density lipoprotein by LDL-apheresis in familial hypercholesterolaemia: a possible activation of the reverse cholesterol transport system","volume":"74","author":"Koizumi","year":"1988","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.plipres.2017.05.001_bb0270","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1160\/TH13-07-0612","article-title":"Circulating CD45+\/CD3+ lymphocyte-derived microparticles map lipid-rich atherosclerotic plaques in familial hypercholesterolaemia patients","volume":"111","author":"Suades","year":"2013","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.plipres.2017.05.001_bb0275","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1749-6632.1994.tb17330.x","article-title":"Molecular genetics of cholesterol transport and cholesterol reverse transport disorders (familial hypercholesterolemia and CETP deficiency) and coronary heart disease","volume":"748","author":"Mabuchi","year":"1995","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"4","key":"10.1016\/j.plipres.2017.05.001_bb0280","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0026-0495(86)90146-0","article-title":"Plasma triglycerides related decrease in high-density lipoprotein cholesterol and its association with myocardial infarction in heterozygous familial hypercholesterolemia","volume":"35","author":"Moorjani","year":"1986","journal-title":"Metab. Clin. Exp."},{"issue":"2","key":"10.1016\/j.plipres.2017.05.001_bb0285","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0021-9150(82)90114-9","article-title":"Coronary artery disease in heterozygous familial hypercholesterolemia","volume":"44","author":"Hirobe","year":"1982","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.plipres.2017.05.001_bb0290","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1053\/euhj.2000.2408","article-title":"Importance of HDL cholesterol levels and the total\/HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia","volume":"22","author":"Real","year":"2001","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.plipres.2017.05.001_bb0295","first-page":"36","article-title":"High-density lipoprotein metabolism in familial hypercholesterolaemia: significance, mechanisms, therapy","volume":"12","author":"Watts","year":"2002","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"5","key":"10.1016\/j.plipres.2017.05.001_bb0300","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1161\/01.ATV.0000218507.95149.42","article-title":"Influence of HDL cholesterol on preclinical carotid atherosclerosis in familial hypercholesterolemia","volume":"26","author":"Junyent","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.plipres.2017.05.001_bb0305","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacl.2012.08.001","article-title":"Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresis","volume":"7","author":"Nenseter","year":"2013","journal-title":"J. Clin. Lipidol."},{"issue":"2","key":"10.1016\/j.plipres.2017.05.001_bb0310","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/01.ATV.11.2.290","article-title":"Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia","volume":"11","author":"Hill","year":"1991","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.plipres.2017.05.001_bb0315","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0021-9150(93)90103-2","article-title":"Relation of lipoprotein (a) to coronary heart disease and duplexsonographic findings of the carotid arteries in heterozygous familial hypercholesterolemia","volume":"101","author":"Tat\u00f2","year":"1993","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.plipres.2017.05.001_bb0320","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1194\/jlr.P016816","article-title":"LDL-apheresis depletes apoE-HDL and pre-\u03b21-HDL in familial hypercholesterolemia: relevance to atheroprotection","volume":"52","author":"Orsoni","year":"2011","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.plipres.2017.05.001_bb0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-511X-10-185","article-title":"Myeloperoxidase modulation by LDL apheresis in familial hypercholesterolemia","volume":"10","author":"Puntoni","year":"2011","journal-title":"Lipids Health Dis."},{"issue":"2","key":"10.1016\/j.plipres.2017.05.001_bb0330","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1073\/pnas.80.2.564","article-title":"Treatment of familial hypercholesterolemia by portacaval anastomosis: effect on cholesterol metabolism and pool sizes","volume":"80","author":"McNamara","year":"1983","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.plipres.2017.05.001_bb0335","doi-asserted-by":"crossref","first-page":"B66","DOI":"10.1016\/S0002-9149(88)80055-9","article-title":"Selective reduction of cholesterol in HDL 2 fraction by probucol in familial hypercholesterolemia and hyperHDL 2 cholesterolemia with abnormal cholesteryl ester transfer","volume":"62","author":"Matsuzawa","year":"1988","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.plipres.2017.05.001_bb0340","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2217\/epi.15.120","article-title":"Epigenetic and genetic variations at the TNNT1 gene locus are associated with HDL-C levels and coronary artery disease","volume":"8","author":"Guay","year":"2016","journal-title":"Epigenomics"},{"issue":"3","key":"10.1016\/j.plipres.2017.05.001_bb0345","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1089\/gte.2006.10.192","article-title":"Different genes and polymorphisms affecting high-density lipoprotein cholesterol levels in Greek familial hypercholesterolemia patients","volume":"10","author":"Dedoussis","year":"2006","journal-title":"Genet. Test."},{"issue":"3","key":"10.1016\/j.plipres.2017.05.001_bb0350","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1023\/A:1005325911665","article-title":"Analysis of CBS alleles in Czech and Slovak patients with homocystinuria: report on three novel mutations E176K, W409X and 1223+ 37 del99","volume":"20","author":"Kozich","year":"1997","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.plipres.2017.05.001_bb0355","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1586\/14737159.7.1.45","article-title":"Unraveling the genetics of atherosclerosis: implications for diagnosis and treatment","volume":"7","author":"Seo","year":"2007","journal-title":"Expert. Rev. Mol. Diagn."},{"issue":"1","key":"10.1016\/j.plipres.2017.05.001_bb0360","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0021-9150(98)00271-8","article-title":"Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery diseases","volume":"143","author":"Tsai","year":"1999","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.plipres.2017.05.001_bb0365","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0002-8703(03)00501-5","article-title":"The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease","volume":"146","author":"Carlquist","year":"2003","journal-title":"Am. Heart J."},{"issue":"7","key":"10.1016\/j.plipres.2017.05.001_bb0370","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/sj.ejhg.5201426","article-title":"TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia","volume":"13","author":"Mohrschladt","year":"2005","journal-title":"Eur. J. Hum. Genet."},{"issue":"5","key":"10.1016\/j.plipres.2017.05.001_bb0375","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1161\/01.ATV.14.5.707","article-title":"Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution","volume":"14","author":"Brinton","year":"1994","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"8","key":"10.1016\/j.plipres.2017.05.001_bb0380","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0022-2275(20)33394-0","article-title":"Apolipoprotein AI kinetics in heterozygous familial hypercholesterolemia: a stable isotope study","volume":"40","author":"Frenais","year":"1999","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.plipres.2017.05.001_bb0385","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.atherosclerosis.2006.02.023","article-title":"Association of heterozygous familial hypercholesterolemia with smaller HDL particle size","volume":"190","author":"Hogue","year":"2007","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.plipres.2017.05.001_bb0390","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.ijcard.2013.06.069","article-title":"The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: developing a new framework for future therapies","volume":"168","author":"Ooi","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.plipres.2017.05.001_bb0395","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.atherosclerosis.2015.09.021","article-title":"Familial hypercholesterolaemia: A global call to arms","volume":"243","author":"Vallejo-Vaz","year":"2015","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.plipres.2017.05.001_bb0400","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.jacc.2005.06.080","article-title":"High-density lipoprotein function: recent advances","volume":"46","author":"Ansell","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.plipres.2017.05.001_bb0405","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0021-9150(89)90127-5","article-title":"Kinetics of HDL-apo AI in the WHHL rabbit, an animal model of familial hypercholesterolemia","volume":"79","author":"Saku","year":"1989","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.plipres.2017.05.001_bb0410","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1161\/01.ATV.12.7.843","article-title":"In vivo metabolism of apolipoprotein AI in a patient with homozygous familial hypercholesterolemia","volume":"12","author":"Schaefer","year":"1992","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"41","key":"10.1016\/j.plipres.2017.05.001_bb0415","doi-asserted-by":"crossref","first-page":"25576","DOI":"10.1074\/jbc.272.41.25576","article-title":"Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas identification, cloning, characterization, and plasma distribution of apolipoprotein L","volume":"272","author":"Duchateau","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.plipres.2017.05.001_bb0420","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/CIRCRESAHA.114.303354","article-title":"Cardiovascular twist to the rapidly evolving apolipoprotein L1 story","volume":"114","author":"Farrall","year":"2014","journal-title":"Circ. Res."},{"issue":"6","key":"10.1016\/j.plipres.2017.05.001_bb0425","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1194\/jlr.P061598","article-title":"ApoL1 levels in high density lipoprotein and cardiovascular event presentation in patients with familial hypercholesterolemia","volume":"57","author":"Cubedo","year":"2016","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.plipres.2017.05.001_bb0430","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1194\/jlr.M400052-JLR200","article-title":"Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia","volume":"46","author":"Van Himbergen","year":"2005","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.plipres.2017.05.001_bb0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2017.64712","article-title":"PoLA\/CFPiP\/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016","volume":"13","author":"Banach","year":"2017","journal-title":"Arch. Med. Sci."},{"issue":"4","key":"10.1016\/j.plipres.2017.05.001_bb0440","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1161\/01.ATV.7.4.401","article-title":"Plasma lipoprotein distribution of apolipoprotein E in familial hypercholesterolemia","volume":"7","author":"Gibson","year":"1987","journal-title":"Arteriosclerosis"},{"issue":"6","key":"10.1016\/j.plipres.2017.05.001_bb0445","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/01.CIR.98.6.519","article-title":"Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins","volume":"98","author":"O'Brien","year":"1998","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.plipres.2017.05.001_bb0450","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jacl.2010.11.001","article-title":"Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: effect of pravastatin","volume":"5","author":"Ryu","year":"2011","journal-title":"Journal of Clinical Lipidology"},{"issue":"1","key":"10.1016\/j.plipres.2017.05.001_bb0455","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1194\/jlr.M030221","article-title":"Structural basis of specific interactions of Lp-PLA2 with HDL revealed by hydrogen deuterium exchange mass spectrometry","volume":"54","author":"Cao","year":"2013","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.plipres.2017.05.001_bb0460","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1161\/ATVBAHA.115.306665","article-title":"Association between cholesterol efflux capacity and atherosclerotic cardiovascular disease in patients with familial hypercholesterolemia","volume":"36","author":"Ogura","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"10","key":"10.1016\/j.plipres.2017.05.001_bb0465","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1194\/jlr.M600109-JLR200","article-title":"Autoantibody titers against OxLDL are correlated with Achilles tendon thickness in patients with familial hypercholesterolemia","volume":"47","author":"Tsouli","year":"2006","journal-title":"J. Lipid Res."},{"issue":"7","key":"10.1016\/j.plipres.2017.05.001_bb0470","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/eci.12643","article-title":"Familial hypercholesterolaemia: cholesterol efflux and coronary disease","volume":"46","author":"Versmissen","year":"2016","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.plipres.2017.05.001_bb0475","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3389\/fphar.2015.00243","article-title":"HDL-S1P: cardiovascular functions, disease-associated alterations, and therapeutic applications","volume":"6","author":"Levkau","year":"2015","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.plipres.2017.05.001_bb0480","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.bbalip.2013.04.009","article-title":"Apolipoprotein M promotes mobilization of cellular cholesterol in vivo","volume":"1831","author":"Elsoe","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"issue":"23","key":"10.1016\/j.plipres.2017.05.001_bb0485","doi-asserted-by":"crossref","first-page":"9613","DOI":"10.1073\/pnas.1103187108","article-title":"Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M","volume":"108","author":"Christoffersen","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.plipres.2017.05.001_bb0490","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/cvr\/cvu139","article-title":"High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease","volume":"103","author":"Kratzer","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.plipres.2017.05.001_bb0495","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/978-3-319-09665-0_11","article-title":"HDL and atherothrombotic vascular disease","volume":"224","author":"Annema","year":"2015","journal-title":"Handb. Exp. Pharmacol."},{"issue":"8","key":"10.1016\/j.plipres.2017.05.001_bb0500","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.metabol.2013.02.008","article-title":"Transfer of lipids to high-density lipoprotein (HDL) is altered in patients with familial hypercholesterolemia","volume":"62","author":"Martinez","year":"2013","journal-title":"Metab. Clin. Exp."},{"issue":"4","key":"10.1016\/j.plipres.2017.05.001_bb0505","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/MOL.0b013e32833c1ef6","article-title":"Marked HDL deficiency and premature coronary heart disease","volume":"21","author":"Schaefer","year":"2010","journal-title":"Curr. Opin. Lipidol."},{"issue":"2","key":"10.1016\/j.plipres.2017.05.001_bb0510","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1194\/jlr.M700362-JLR200","article-title":"Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency","volume":"49","author":"Santos","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.plipres.2017.05.001_bb0515","doi-asserted-by":"crossref","DOI":"10.1186\/1476-511X-10-185","article-title":"Myeloperoxidase modulation by LDL apheresis in familial hypercholesterolemia","volume":"10","author":"Puntoni","year":"2011","journal-title":"Lipids Health Dis."},{"issue":"4","key":"10.1016\/j.plipres.2017.05.001_bb0520","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jacl.2010.02.011","article-title":"No evidence of impaired endothelial function or altered inflammatory state in patients with familial hypercholesterolemia treated with statins","volume":"4","author":"Hovland","year":"2010","journal-title":"Journal of Clinical Lipidology"},{"issue":"18","key":"10.1016\/j.plipres.2017.05.001_bb0525","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.clinbiochem.2014.09.006","article-title":"Enhanced reduction in oxidative stress and altered glutathione and thioredoxin system response to unsaturated fatty acid load in familial hypercholesterolemia","volume":"47","author":"Cortes","year":"2014","journal-title":"Clin. Biochem."},{"issue":"2","key":"10.1016\/j.plipres.2017.05.001_bb0530","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0021-9150(00)00677-8","article-title":"Measures of oxidative stress in heterozygous familial hypercholesterolaemia","volume":"156","author":"Nourooz-Zadeh","year":"2001","journal-title":"Atherosclerosis"},{"issue":"15","key":"10.1016\/j.plipres.2017.05.001_bb0535","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.clinbiochem.2010.07.022","article-title":"Malondialdehyde (MDA) and protein carbonyl (PCO) levels as biomarkers of oxidative stress in subjects with familial hypercholesterolemia","volume":"43","author":"Pirinccioglu","year":"2010","journal-title":"Clin. Biochem."},{"issue":"2","key":"10.1016\/j.plipres.2017.05.001_bb0540","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.atherosclerosis.2007.08.011","article-title":"Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemia","volume":"197","author":"Meuwese","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.plipres.2017.05.001_bb0545","doi-asserted-by":"crossref","unstructured":"T.M. Van Himbergen, L.J.H. Van Tits, M.P.C. Hectors, J. De Graaf, M. Roest, A.F.H. Stalenhoef, Paraoxonase-1 and linoleic acid oxidation in familial hypercholesterolemia, Biochem. Biophys. Res. Commun. 333(3) (2005) 787\u2013793.","DOI":"10.1016\/j.bbrc.2005.05.176"},{"issue":"5985","key":"10.1016\/j.plipres.2017.05.001_bb0550","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1126\/science.1189123","article-title":"MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis","volume":"328","author":"Najafi-Shoushtari","year":"2010","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.plipres.2017.05.001_bb0555","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ncb2210","article-title":"MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins","volume":"13","author":"Vickers","year":"2011","journal-title":"Nat. Cell Biol."},{"issue":"11","key":"10.1016\/j.plipres.2017.05.001_bb0560","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1042\/CS20150235","article-title":"Circulating miR-33a and miR-33b are up-regulated in familial hypercholesterolaemia in paediatric age","volume":"129","author":"Martino","year":"2015","journal-title":"Clin. Sci. (Lond.)"},{"issue":"7","key":"10.1016\/j.plipres.2017.05.001_bb0565","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1172\/JCI57275","article-title":"Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis","volume":"121","author":"Rayner","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.plipres.2017.05.001_bb0570","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1194\/jlr.R036327","article-title":"A big role for small RNAs in HDL homeostasis","volume":"54","author":"Ouimet","year":"2013","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.plipres.2017.05.001_bb0575","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1006\/bbrc.2000.4061","article-title":"Accumulation of RhoA, RhoB, RhoG, and Rac1 in fibroblasts from tangier disease subjects suggests a regulatory role of rho family proteins in cholesterol efflux","volume":"280","author":"Utech","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.plipres.2017.05.001_bb0580","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1161\/CIRCRESAHA.115.305467","article-title":"Cholesterol homeostasis regulation by miR-223: basic science mechanisms and translational implications","volume":"116","author":"Nishi","year":"2015","journal-title":"Circ. Res."},{"issue":"6","key":"10.1016\/j.plipres.2017.05.001_bb0585","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/ATVBAHA.112.300741","article-title":"Characterization of levels and cellular transfer of circulating lipoprotein-bound microRNAs","volume":"33","author":"Wagner","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.plipres.2017.05.001_bb0590","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1161\/CIRCRESAHA.114.300645","article-title":"MicroRNA control of high-density lipoprotein metabolism and function","volume":"114","author":"Rayner","year":"2014","journal-title":"Circ. Res."},{"issue":"7","key":"10.1016\/j.plipres.2017.05.001_bb0595","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1161\/ATVBAHA.110.207142","article-title":"Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib","volume":"30","author":"Yvan-Charvet","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"11","key":"10.1016\/j.plipres.2017.05.001_bb0600","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1194\/jlr.M016410","article-title":"Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters","volume":"52","author":"Castro-Perez","year":"2011","journal-title":"J. Lipid Res."},{"issue":"6","key":"10.1016\/j.plipres.2017.05.001_bb0605","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1161\/01.CIR.0000086981.09834.E0","article-title":"Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo","volume":"108","author":"Zhang","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.plipres.2017.05.001_bb0610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2016.11.019","article-title":"Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages","volume":"256","author":"Adorni","year":"2017","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.plipres.2017.05.001_bb0615","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.atherosclerosis.2012.04.006","article-title":"Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia","volume":"223","author":"Abifadel","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.plipres.2017.05.001_bb0620","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2016.05.005","article-title":"Lomitapide affects HDL composition and function","volume":"251","author":"Yahya","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.plipres.2017.05.001_bb0625","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-319-09665-0_1","article-title":"Structure of HDL: particle subclasses and molecular components","volume":"224","author":"Kontush","year":"2015","journal-title":"Handb. Exp. Pharmacol."},{"issue":"6","key":"10.1016\/j.plipres.2017.05.001_bb0630","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrd4279","article-title":"HDL-targeted therapies: progress, failures and future","volume":"13","author":"Kingwell","year":"2014","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Progress in Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163782717300115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163782717300115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T14:28:18Z","timestamp":1659018498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163782717300115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":126,"alternative-id":["S0163782717300115"],"URL":"https:\/\/doi.org\/10.1016\/j.plipres.2017.05.001","relation":{},"ISSN":["0163-7827"],"issn-type":[{"value":"0163-7827","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HDL abnormalities in familial hypercholesterolemia: Focus on biological functions","name":"articletitle","label":"Article Title"},{"value":"Progress in Lipid Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.plipres.2017.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}